Bioorganic & medicinal chemistry letters · 2024
Discovery of potent dihydro-oxazinoquinolinone inhibitors of GuaB for the treatment of tuberculosis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Yuebiao, Aliagas Ignacio, Wang Shumei, Li Chun Sing, Liu Zhiguo, Bowman Christine M, Burdick Daniel J, Clark Kevin R, Dening Tahnee J, Flygare John, Ganti Anjani, Girgis Hany S, Hanan Emily J, Harris Seth F, Hu Chloe, Kapadia Sharookh B, Koehler Michael F T, Lai Tommy, Liang Jun, Liu Xingrong, Ma Fang, Mao Jialin, Nicolai Jeremy, Sims Jessica, Unhayaker Savita, Wai John, Wang Xiaojing, Wu Ping, Xu Yiming, Yen Chun-Wan, Zhang Renwei, Elfert Torben F, Tan Man-Wah, Kofoed Eric M, Crawford Terry D
Аннотация
Tuberculosis is the leading cause of death from an infectious disease, and is caused by Mycobacterium tuberculosis (M.tb). More than 1 billion people worldwide are thought to harbor an M.tb infection. The multidrug therapy that represents the current standard of care requires a minimum of four months of dosing and drug resistant Mycobacterium tuberculosis treatment regimens are significantly longer. Inosine-5'-monophosphate dehydrogenase (GuaB) is the enzyme that performs the rate-limiting step in de novo guanine nucleotide biosynthesis that is critical for growth and viability of bacteria including M.tb. The development of a novel antibiotic that inhibits GuaB could combine with existing therapies in novel ways and thereby contribute to effective therapeutic regimens for the treatment of tuberculosis. Here we describe the discovery of structurally distinct small molecule GuaB inhibitors that are potent against M.tb H37Ra and H37Rv strains and have desirable safety and ADME profiles.